It is Time to Explore the Potential Benefit of Routine Micronutrient Supplementation in Optimizing Bone Health and Growth in HIV Exposed Uninfected Children in the Context of Early Antiretroviral Exposure in Resource Limited Settings

Authors

  • Moreen Kamateeka African Field Epidemiology Network (AFENET) Nigeria, 50 Hallie Selassie St, Asokoro, Abuja, Nigeria; Makerere University - Johns Hopkins University Research Collaboration, Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda There is evidence that human immunodeficiency virus (HIV) infected children have decreased bone mineral density (BMD) compared to population norms.
  • Dorothy Sebikari Makerere University - Johns Hopkins University Research Collaboration, Upper Mulago Hill Road, P.O. Box 23491, Kampala, Uganda There is evidence that human immunodeficiency virus (HIV) infected children have decreased bone mineral density (BMD) compared to population norms.

DOI:

https://doi.org/10.17140/HARTOJ-4-e010

Abstract

There is evidence that human immunodeficiency virus (HIV) infected children have decreased bone mineral density (BMD) compared to population norms.1-4 Similarly, several studies have shown impaired growth among HIV infected children with several patterns of disrupted growth.5-7 Among other factors, micronutrient deficiencies are believed to contribute significantly to growth failure in HIV infected children, particularly in resource constrained settings with high background rates of micronutrient deficiencies.

Downloads

Published

2017-09-26

How to Cite

Moreen Kamateeka, & Dorothy Sebikari. (2017). It is Time to Explore the Potential Benefit of Routine Micronutrient Supplementation in Optimizing Bone Health and Growth in HIV Exposed Uninfected Children in the Context of Early Antiretroviral Exposure in Resource Limited Settings. HIV/AIDS/Research/and/Treatment, 4(1), e1-e4. https://doi.org/10.17140/HARTOJ-4-e010

Issue

Vol. 4 No. 1 (2017): Volume 4 Issue 1 2017

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in HIV/AIDS Research and Treatment (HRT) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.